187 results on '"Randon, G"'
Search Results
2. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
3. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
4. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
5. O-8 Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies
6. O-6 Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO
7. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
8. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
9. THE EMERGING ROLE OF IMMUNOTHERAPY IN GASTROESOPHAGEAL CANCER: STATE OF ART AND FUTURE PERSPECTIVE
10. SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study
11. O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study
12. Family and community nursing (FCN): guidelines of the network of Master for FCN of Italian Universities
13. 223P Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
14. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
15. SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
16. SO-13 Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
17. P-160 Mismatch repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy
18. PD-26 Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: A large, multicenter, cohort study
19. 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
20. atypical RAS mutations in metastatic colorectal cancer
21. Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells
22. Lo strumento italiano di misurazione della qualità dell’apprendimento clinico degli studenti infermieri. [The Italian instrument evaluating the nursing students clinical learning quality]
23. DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
24. P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients
25. P1.04-38 Efficacy and Safety of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer
26. MA03.10 Prospective Evaluation of a Prognostic Clinico-Molecular Score (DEMo) to Predict Outcome of Advanced NSCLC Patients Treated with Immunotherapy
27. P2.09-05 Clinical and Biological Characterization of Lung Enteric Adenocarcinoma
28. Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO
29. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies
30. EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
31. Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
32. Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei
33. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
34. Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)
35. Strumento di Valutazione Italiano degli Ambienti di Tirocinio per gli studenti infermieri (SVIAT): protocollo di validazione [Validation of the Italian Clinical Learning Environment Instrument (SVIAT): study protocol]
36. 570P - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO
37. 112P - DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
38. PD-015 - Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies
39. 581P - Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei
40. PD-017 - Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)
41. I progetti gestiti dai Coordinatori: analisi del loro profilo e successo
42. Intraperitoneal chemotherapy in pretreated ovarian cancer patients: a retrospective case-control study
43. Parameters governing bacterial growth in water distribution systems
44. PARTICULATE PRODUCTS AND NEW POLYMERS FOR A MORE EFFICIENT REMOVAL OF DISSOLVED ORGANIC MATTER IN DRINKING WATER RESOURCES
45. Influence of porosity and surface chemistry of commercially available powdered activated carbons for the removal of dissolved organic carbon
46. Etude d'un réseau à très faible teneur en matière organique biodégradable : le réseau de la ville de Nice
47. Studies of BDOC and bacterial dynamics in the drinking water distribution system of the Northern Parisian suburbs
48. Mesures de la qualité des rivières : stations automatiques
49. An Industrial Analyzer by a Potentiometric Method for Total Organic Carbon in Water.
50. Water quality in rivers: automatic measuring stations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.